azenosertib (ZN-c3) / Zentalis Pharma 
Welcome,         Profile    Billing    Logout  

16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
azenosertib (ZN-c3) / Zentalis Pharma
ZN-c3-004, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Active, not recruiting
2
76
Canada, US, RoW
ZN-c3, azenosertib, KP-2638
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Uterine Serous Carcinoma
11/24
05/25
NCT06369155: Azenosertib in Uterine Serous Carcinoma: Biomarker Study

Not yet recruiting
2
25
US
Azenosertib, Zn-c3, C29H34N8O2
Joyce Liu, MD, National Cancer Institute (NCI), Zentalis
Uterine Serous Carcinoma, Uterine Carcinoma, Uterine Cancer
01/26
01/27
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
NCT06015659: ZN-c3 + Gemcitabine in Pancreatic Cancer

Recruiting
2
34
US
Zentalis, Zn-c3, KP-2638, azenosertib, C29H34N8O2., Gemzar, Gemcitabine hydrochloride, FF 10832, LY188011, C9H11F2N3O4 - HCl
Brandon Huffman, Lustgarten Foundation, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, Stand Up To Cancer
Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
06/26
06/27
ZN-c3-003, NCT04833582 / 2021-000021-27: A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma

Hourglass Jan 2024 - Jun 2024 : Final results from ZN-c3-003 trial in osteosarcoma
Active, not recruiting
1/2
84
Europe, US
ZN-c3, Gemcitabine, Gemzar
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Osteosarcoma
08/23
12/23
ZN-c3-006, NCT05198804: A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Active, not recruiting
1/2
117
Europe, US
ZN-c3, Niraparib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
05/25
05/25
ZAP-IT, NCT06351332: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Recruiting
1/2
78
US
Azenosertib, ZN-c3, KP-2638, Carboplatin, C6H12N2O4Pt, platinum, diammine[1,1-cyclobutanedicarboxylato(2-)- O,O']-, (SP-4-2), Pembrolizumab, Keytruda, MK-3475, Humanized X PD-1-mAB (H409A11) IgG4, C6504H10004N1716O2036S46
Filipa Lynce, MD, Merck Sharp & Dohme LLC, Zentalis Pharmaceuticals
Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
03/27
09/29
NCT05682170: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Jul 2023 - Dec 2023: Preliminary data from trial in combination with ZN-d5 for r/r/ AML
Recruiting
1/2
95
US
ZN-d5 ZN-c3, Study Drug, ZN-c3
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Acute Myeloid Leukemia (AML)
03/25
02/26
ZN-c3-016, NCT05743036: ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Hourglass Jan 2023 - Mar 2023 : Initiation of P1/2 dose escalation study of ZN-c3 in combination with encorafenib & cetuximab in patients with BRAF V600E-mutated metastatic CRC
Recruiting
1/2
82
Europe, US, RoW
ZN-c3, Encorafenib, BRAFTOVI®, Cetuximab, ERBITUX®
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, Pfizer
Metastatic Colorectal Cancer
08/26
09/26
NCT04972422: A Phase 1b Study of ZN-c3 in Chinese Subjects

Recruiting
1b
38
RoW
ZN-c3, Study Drug
Zentera Therapeutics HK Limited
Solid Tumors
06/22
06/23
ZN-c3-001, NCT04158336: A Study of ZN-c3 in Participants With Solid Tumors

Recruiting
1
146
US
ZN-c3, Study Drug
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Solid Tumor
05/23
08/23
ZN-c3-002, NCT04516447: A Study of ZN-c3 in Patients With Ovarian Cancer

Jul 2023 - Dec 2023: Data from trial in combination with chemotherapy for platinum-resistant ovarian cancer
Recruiting
1
140
Europe, US, RoW
ZN-c3, Study drug, Azenosertib, Carboplatin, Pegylated liposomal doxorubicin, Paclitaxel, Gemcitabine, Bevacizumab
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
12/24
02/27
NCT04005690: Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Recruiting
1
80
US
Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Onvansertib, 'PLK1 Inhibitor PCM-075, NMS-1286937, PCM 075, PCM-075, PLK-1 Inhibitor PCM-075, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 1 Inhibitor PCM-075, Azenosertib, ZN-c3, KP-2638, C29H34N8O2
OHSU Knight Cancer Institute, American Association for Cancer Research, Oregon Health and Science University, Genentech, Inc., Cardiff Oncology
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
06/26
02/28
NCT06364410: Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Not yet recruiting
1
48
NA
Azenosertib, Wee1 Inhibitor ZN-c3, ZN c3, ZN-c3, ZNc3, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516
National Cancer Institute (NCI)
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm
03/26
03/26
NCI-2022-03599, NCT05368506: ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer

Withdrawn
1
14
NA
Wee1 Inhibitor ZN-c3, ZN c3, ZN-c3, ZNc3
OHSU Knight Cancer Institute, Oregon Health and Science University
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
09/24
07/25
NCT06109883: LB-100 (PP2A Inhibitor) and Azenosertib (WEE1 Inhibitor) in Metastatic Colorectal Cancer Patients

Not yet recruiting
1
43
NA
LB-100, PP2 inhibitor, Azenosertib, WEE1 inhibitor, ZN-c3
The Netherlands Cancer Institute
Metastatic Colorectal Cancer
11/26
11/26

Download Options